Table 1 Demographic and clinical characteristics of study patients
Variables | Patients received metformin (n = 32) | Placebo group (n = 31) | p-value |
|---|---|---|---|
Male/Female | 17/15 | 14/17 | 0.352 |
Age (y) | 51.9 ± 10.9 | 55.2 ± 14.0 | 0.306 |
BMI (kg/m²) | 32.6 ± 5.8 | 31.5 ± 5.6 | 0.410 |
Current smokers, n (%) | 4 (12.5%) | 2 (6.5%) | 0.391 |
Hypertension, n (%) | 15 (46.9%) | 15 (48.4%) | 0.599 |
Dyslipidemia, n (%) | 21 (65.6%) | 14 (45.2%) | 0.079 |
DM/IFG, n (%) | 6/14(18.8/43.8%) | 2/13 (6.5/41.9%) | 0.128 |
Concomitant medication: | Â | Â | Â |
 Antidiabetic treatment (%) | 6 (18.8%) | 2 (6.5%) | 0.194 |
 Statins (%) | 18 (56.3%) | 11 (35.5%) | 0.079 |
 ACEIs/ARBs (%) | 9 (28.1%) | 9 (29.0%) | 0.609 |
 Diuretics (%) | 1 (3.1%) | 6 (19.4%) | 0.104 |
 B-blockers (%) | 9 (28.1%) | 10 (32.3%) | 0.784 |
 CCB-blockers (%) | 5 (15.6%) | 8 (25.8%) | 0.351 |
 Aspirin (%) | 13 (40.6%) | 9 (29.0%) | 0.292 |
Baseline systolic BP (mm/Hg) | 138.8 ± 17.6 | 133.6 ± 18.1 | 0.258 |
Baseline diastolic BP (mm/Hg) | 80.1 ± 9.8 | 74.6 ± 13.5 | 0.072 |
Baseline heart rate (bts/min) | 68.6 ± 12.3 | 62.9 ± 8.4 | 0.034 |
Baseline fasting glucose (mg/dl) | 131.8 ±51.3 | 98.3 ± 14.8 | 0.001 |
Baseline total cholesterol (mg/dl) | 184.5 ± 43.3 | 191.1 ± 37.0 | 0.523 |
Baseline LDL Cholesterol (mg/dl) | 110.4 ± 37.9 | 112.7 ± 34.2 | 0.811 |
Baseline HDL-cholesterol (mg/dl) | 42.6 ± 13.0 | 48.2 ± 15.2 | 0.123 |
Baseline triglycerides (mg/dl) | 185.5 ± 112.0 | 143.1 ± 63.2 | 0.070 |
Baseline hs-CRP (mg/dl) | 0.9 ± 1.1 | 0.9 ± 1.4 | 0.969 |
Baseline AST (U/l) | 28.9 ± 16.8 | 28.0 ± 8.2 | 0.796 |
Baseline ALT (U/l) | 38.0 ± 29.9 | 32.6 ± 15.3 | 0.377 |
Baseline ALP (U/l) | 67.7 ± 17.0 | 72.2 ± 23.5 | 0.386 |
Baseline creatinine (mg/dl) | 0.9 ± 0.1 | 0.9 ± 0.2 | 0.723 |
Baseline urea (mg/dl) | 32.0 ± 10.0 | 32.0 ± 9.0 | 1.000 |
Baseline adiponectine (ng/ml) | 6130.5 ± 2872.6 | 9156.3 ± 6365.2 | 0.020 |
Baseline AI (%) | 31.4 ± 11.1 | 30.0 ± 10.7 | 0.628 |